Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
复制标题
DOI：
10.1038/nm988
复制
发表时间：
2004-02-01
期刊：
影响因子：
82.9
通讯作者：
Jain, RK
中科院分区：
文献类型：
--
作者：
Willett, CG;Boucher, Y;Jain, RK
血管内皮生长因子（VEGF）阻断对人类肿瘤血管生物学的影响尚不清楚。在这里，我们在这里表明，一个单一的输注VEGF特异性抗体贝伐单抗减少肿瘤灌注，血管体积，微血管密度，间质液压力和数量的活的，循环内皮细胞和祖细胞，并增加了部分血管与周细胞覆盖直肠癌患者。这些数据表明，VEGF阻断在人肿瘤中具有直接和快速的抗血管效应。
The effects of vascular endothelial growth factor (VEGF) blockade on the vascular biology of human tumors are not known. Here we show here that a single infusion of the VEGF-specific antibody bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure and the number of viable, circulating endothelial and progenitor cells, and increases the fraction of vessels with pericyte coverage in rectal carcinoma patients. These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors.